Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.49 |
| ▸ | MAP2K2 | P36507 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388205 | 0.89 | MEN1 (0.53) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL2387610 | 0.85 | MAP2K1 (0.53) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL14594276 | 0.85 | MAP2K1 (0.51) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL7161001 | 0.84 | MEN1 (0.57) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL6035714 | 0.83 | MEN1 (0.47) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL6036025 | 0.83 | MAP2K1 (0.59) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5391585 | 0.82 | MAP2K1 (0.56) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL5384161 | 0.82 | MEN1 (0.62) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL27573777 | 0.81 | MAP2K1 (0.53) | MEN1KMT2ATDP1MAP2K1MAP2K2 | |
| SCHEMBL28748333 | 0.81 | MAP2K1 (0.52) | MEN1KMT2ATDP1MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0993437-B1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2006-11-08 | — | — | EP | claimed |
| US-20030149015-A1 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | BARRETT STEPHEN DOUGLAS (US) | 2003-08-07 | — | — | US | claimed |
| US-6492363-B2 | FOR THERAPY OF CANCER AND OTHER PROLIFERATIVE DISEASES SUCH AS INFLAMMATION, PSORIASIS AND RESTENOSIS, AS WELL AS STROKE, HEART FAILURE, AND IMMUNODEFICIENCY DISORDERS | WARNER-LAMBERT COMPANY | 2002-12-10 | — | — | US | claimed |
| US-20020022647-A1 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | BARRETT STEPHEN DOUGLAS (US) | 2002-02-21 | — | — | US | claimed |
| EP-0993437-B1 | 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149015-A1 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | BCOR, BCL6, CBR1 | MEN1 4401/4885KMT2A 2516/4885TDP1 3804/4885 |
| US-20020022647-A1 | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | BCOR, BCL6, CBR1 | MEN1 4401/4885KMT2A 2516/4885TDP1 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.